WO2010109610A1 - Pharmaceutical composition container - Google Patents

Pharmaceutical composition container Download PDF

Info

Publication number
WO2010109610A1
WO2010109610A1 PCT/JP2009/055972 JP2009055972W WO2010109610A1 WO 2010109610 A1 WO2010109610 A1 WO 2010109610A1 JP 2009055972 W JP2009055972 W JP 2009055972W WO 2010109610 A1 WO2010109610 A1 WO 2010109610A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
swallowing
container
composition container
storage
Prior art date
Application number
PCT/JP2009/055972
Other languages
French (fr)
Japanese (ja)
Inventor
修司 盛本
Original Assignee
株式会社モリモト医薬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社モリモト医薬 filed Critical 株式会社モリモト医薬
Priority to PCT/JP2009/055972 priority Critical patent/WO2010109610A1/en
Priority to KR1020117024735A priority patent/KR20110131295A/en
Priority to CN2010800119716A priority patent/CN102438575A/en
Priority to US13/257,424 priority patent/US20120012480A1/en
Priority to EP10756162.3A priority patent/EP2412357A4/en
Priority to JP2011506110A priority patent/JPWO2010110366A1/en
Priority to PCT/JP2010/055212 priority patent/WO2010110366A1/en
Publication of WO2010109610A1 publication Critical patent/WO2010109610A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0046—Cups, bottles or bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2024—Separating means having peelable seals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0053—Syringes, pipettes or oral dispensers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3261—Flexible containers having several compartments
    • B65D81/3266—Flexible containers having several compartments separated by a common rupturable seal, a clip or other removable fastening device

Definitions

  • the present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container capable of reducing the residual amount of the pharmaceutical composition.
  • Patent Document 1 discloses a multi-chamber container.
  • This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state.
  • the other space contains a dense fluid substance in a sealed state.
  • Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.
  • Patent Document 1 when the pharmaceutical composition is a powder, powder or granule, there is a problem that there is a high possibility that they remain in the multi-chamber container.
  • the technical problem of the present invention was made to solve the above problems, and an object of the present invention is to provide a pharmaceutical composition container that can reduce the residual amount of the pharmaceutical composition. .
  • the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 has a plurality of spaces 30, 32, 34, 36, 38, 100, 102,110,112,114,116,150. Between two adjacent spaces 70, 71, 72, 76 are closed. The space 70, 71, 72, 76 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18.
  • the swallowing assisting substance 40 is accommodated in the swallowing assisting substance accommodating chambers 30, 100, 102, 104, 106 which are at least one of the spaces.
  • the storages 42 and 120 are stored in the storage chambers 32 and 110, which are at least one of the spaces.
  • the inclusions 42 and 120 contain a pharmaceutical composition 80.
  • the pharmaceutical composition containers 10, 11, 12, 14, 15, 16, 18 are provided with an opening formation scheduled portion 60.
  • the opening formation scheduled portion 60 is a portion where the opening is scheduled to be formed.
  • the opening communicates the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 with the spaces 30, 32, 34, 36, 38, 100, 102, 110, 112, 114, 116, 150.
  • the space 70, 71, 72, 76 between two adjacent spaces opens when a force applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 is applied.
  • the swallowing auxiliary substance 40 is moved from the swallowing auxiliary substance containing chambers 30, 100, 102, 104, 106 to the inclusion holding chambers 32, 110, 112, 114. It becomes possible to guide to.
  • the opening is formed in the opening formation scheduled portion 60, the opening is applied to the mouth of a person who has difficulty in swallowing, and when the swallowing auxiliary substance 40 and the inclusion 42 are pushed out of the opening, the swallowing auxiliary substance 40 is wrapped.
  • the inclusion 42 enters the mouth of a person who is difficult to swallow in a rare state.
  • the inclusion 42 is swallowed. Since the pharmaceutical composition 80 is contained in the storage 42, when the storage 42 is pushed out, the pharmaceutical composition 80 in the storage 42 is also pushed out at the same time. As a result, the residual amount of the pharmaceutical composition 80 in the storage container 32 is lower than when the pharmaceutical composition 80 is not contained in the storage 42.
  • the above-described swallowing auxiliary substance 40 contains water.
  • the material of the inclusion 42 is a water-soluble substance.
  • the above-described swallowing aid substance 40 is a jelly containing moisture.
  • the water-soluble substance is starch.
  • an empty room 116 which is at least one of the above-described spaces, be disposed between the swallowing auxiliary substance storage chamber 102 and the stored material storage chambers 32 and 114.
  • the vacant space 116 is provided, the swallowing aid substance 40 is contained in the inclusion 42 when the two adjacent spaces 102 and 114 communicate with each other against the intention of the user or the handler of the pharmaceutical composition container 15. The possibility of touching is reduced. If the possibility becomes low, the possibility that the encapsulated material 42 will dissolve before taking the pharmaceutical composition 80 also becomes low. As a result, the pharmaceutical composition container 15 is easy to store and easy to handle.
  • the surface of the inclusion 42 described above dissolves in the components of the swallowing auxiliary substance 40.
  • the surface of the inclusion 42 is dissolved with respect to the component of the swallowing auxiliary substance 40, after the swallowing auxiliary substance 40 is guided to the inclusion containing chamber 32, the surface of the inclusion 42 is dissolved. Since the surface is melted while being wrapped in the swallowing auxiliary substance 40, even if it is difficult for the person to swallow, the stored item 42 can be swallowed easily. By swallowing the inclusion 42, the pharmaceutical composition 80 is also swallowed.
  • sealing in the present specification means being closed so that there is no gap.
  • the residual amount of the pharmaceutical composition can be reduced.
  • FIG. 1 is a partially cutaway view of a pharmaceutical composition container 10 according to the present embodiment.
  • FIG. 2 is a diagram illustrating a usage state of the pharmaceutical composition container 10 according to the present embodiment.
  • the pharmaceutical composition container 10 is affixed around the sheets 20 and 20 made of two synthetic resins that are superposed on each other (preferably a soft material that can be folded, such as low-density polyethylene). It is formed by combining.
  • a swallowing auxiliary substance storage chamber 30, a stored material storage chamber 32, and an outlet chamber 34 are formed in the pharmaceutical composition container 10.
  • the swallowing auxiliary substance storage chamber 30, the inclusion storage chamber 32, and the outlet chamber 34 are formed so as to maintain airtightness with respect to the external space.
  • the swallowing auxiliary substance storage chamber 30, the stored item storage chamber 32, and the outlet chamber 34 are arranged in a line.
  • a swallowing assistance substance 40 is housed in the swallowing assistance substance accommodation chamber 30.
  • the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water.
  • the moisture content of the jelly is set so as to ensure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the inclusion 42 described later until the inclusion 42 is completely dissolved.
  • the exit chamber 34 in this embodiment is an empty room.
  • a storage 42 made of oblate is stored in the storage room 32.
  • a granulated drug or other pharmaceutical composition 80 is accommodated in the inclusion 42.
  • the inclusion 42 according to the present embodiment is obtained by putting the pharmaceutical composition 80 in a commercially available wafer and twisting a portion corresponding to the entrance of the pharmaceutical composition 80. Thereby, the stored item 42 is sealed.
  • a starch wafer having a thickness of 10 ⁇ m is used. This is used in order to secure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the storage 42 until the storage 42 is completely dissolved.
  • the thickness of the wafer should be appropriately selected according to the material.
  • a gas for example, nitrogen gas
  • nitrogen gas that does not affect the pharmaceutical composition 80 and the swallowing auxiliary substance 40 is sealed in the storage container 32 and the swallowing auxiliary substance holding room 30 as necessary.
  • the swallowing auxiliary substance storage chamber 30 and the stored material storage chamber 32 are partitioned by a first weak seal portion 70.
  • the inclusion storage chamber 32 and the outlet chamber 34 are partitioned by a second weak seal portion 72.
  • the first weak seal portion 70 and the second weak seal portion 72 are portions between two adjacent spaces among the bonded portions of the two sheets 20 and 20.
  • the strength of the first weak seal portion 70 and the second weak seal portion 72 is such that the outer peripheral strong seal portion 74 (the first weak seal portion 70 and the second weak seal among the portions where the two sheets 20 and 20 are bonded together). It is lower than the strength of the portion other than the seal portion 72). This can be achieved by using different materials for the adhesive when the two sheets 20 and 20 are bonded together.
  • the swallowing auxiliary substance storage chamber 30 when the first weak seal portion 70 and the second weak seal portion 72 are pushed from the outside of the pharmaceutical composition container 10 when the swallowing auxiliary substance storage chamber 30 or the inclusion storage chamber 32 is pushed out of the pharmaceutical composition container 10, the swallowing auxiliary substance storage chamber 30. Or it peels easily with the force which the swallowing auxiliary
  • a pair of cut portions 50 each having a V-shaped cut are formed on both sides of the exit chamber 34.
  • the opening formation scheduled portion 60 sandwiched between the cut portions 50 is a portion where the opening is scheduled to be formed. This opening allows the outside and the inside of the outlet chamber 34 to communicate with each other.
  • a caregiver or the like pushes the swallowing auxiliary substance storage chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal portion 70 by pressure from the inside of the swallowing auxiliary substance storage chamber 30.
  • the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32.
  • the pushed swallowing auxiliary substance 40 spreads in the storage container chamber 32 and fills the periphery of the storage object 42. From this time, the surface of the inclusion 42 starts to melt by the swallowing aid 40.
  • the swallowing auxiliary substance 40 After the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32, a caregiver, a patient 90, or the like squeezes the pharmaceutical composition container 10 in the direction from the swallowing auxiliary substance storage chamber 30 toward the storage container chamber 32. Thereby, as a result of the pressure being applied to the swallowing auxiliary substance 40, the second weak seal portion 72 is peeled off. When the second weak seal portion 72 is peeled off, the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34. When the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34, a caregiver, a patient 90, or the like applies a shearing force to the incision portion 50 to provide an opening in the outlet chamber 34.
  • FIG. 2 shows a situation where the patient 90 is squeezing the pharmaceutical composition container 10.
  • the surface of the inclusion 42 is dissolved in the component of the swallowing auxiliary substance 40, the surface of the inclusion 42 is easily slipped. Since the surface of the inclusion 42 is easy to slide, the inclusion 42 is swallowed smoothly.
  • the pharmaceutical composition container 10 has the following effects.
  • the first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily.
  • the second effect is that the taste such as the bitterness of the drug is suppressed.
  • the third effect is an effect that the pharmaceutical composition 80 can be prevented from being scattered in the mouth.
  • the fourth effect is that there is no need to worry about the stability of the drug.
  • the fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing.
  • the sixth effect is that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (in the case of the present embodiment, the residual amount can be made an amount close to zero). .
  • the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. At this time, the surface of the inclusion 42 is melted. Since the surface is melted while being wrapped in the swallowing assisting material 40, even the patient 90 who is difficult to swallow can easily swallow the stored matter 42. Since the encapsulated product 42 contains the pharmaceutical composition 80, the medicinal composition 80 is also swallowed by swallowing the encapsulated product 42. Thereby, the pharmaceutical composition 80 can be swallowed easily.
  • the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40.
  • the pharmaceutical composition 80 which is the content of the stored product 42 is double-wrapped by the swallowing auxiliary substance 40 and the stored product 42. Since the pharmaceutical composition 80 is wrapped in a double layer, even if the pharmaceutical composition 80 is a drug, the possibility that the tongue of the patient 90 senses its taste such as bitterness is low. As a result, the taste such as the bitterness of the drug is suppressed.
  • the pharmaceutical composition 80 is double-wrapped by the swallowing auxiliary substance 40 and the inclusion 42. Thereby, the possibility that the pharmaceutical composition 80 is scattered in the mouth of the patient 90 is reduced. As a result, scattering of the pharmaceutical composition 80 in the mouth can be suppressed.
  • the drug is a chemical substance. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the drug loses its medicinal properties. For this reason, in many cases, a plurality of drugs cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check in advance whether their medicinal properties are lost.
  • the pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. Storing one type of drug in each space and storing a plurality of drugs separately are substantially the same. This is the reason why it is not necessary to worry about the stability of the drug if the pharmaceutical composition container 10 according to this embodiment is used. Since there is no need to worry about the stability of the drugs, there is no need to examine in advance whether the efficacy of a plurality of drugs has been lost.
  • the fifth effect will be described. After the swallowing assisting substance 40 is guided to the storage container chamber 32, the swallowing assisting substance 40 and the storing object 42 are swallowed, so that the activity of the pharmaceutical composition 80 itself does not have a great influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.
  • the container 42 according to the present embodiment is sealed. Since it is sealed, the possibility of the pharmaceutical composition 80 leaking out of the inclusion 42 is very low. Since the possibility is extremely low, the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (actually, the residual amount is made close to zero).
  • the pharmaceutical composition container 10 described in the present embodiment is illustrated to embody the technical idea of the present invention. This does not limit the material of the sheet 20 to the above-described embodiment. This does not limit the shape of the sheet 20, the shape of each space, the shape of the opening, their dimensions, their structure, their arrangement, and the like to the above-described embodiment.
  • the pharmaceutical composition container 10 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.
  • FIG. 3 is a partially cutaway view of the pharmaceutical composition container 12 according to the first modification.
  • the first tapered portion 130 of the swallowing auxiliary substance storage chamber 100 that faces the storage container 110 is gradually narrowed toward the storage container 110.
  • the 2nd taper part 140 which opposes the swallowing auxiliary substance storage chamber 100 among the inclusion storage rooms 110 is gradually narrowed toward the swallowing auxiliary substance storage chamber 100.
  • a bag-like inclusion 120 as shown in FIG. 3 may be accommodated.
  • the stored item 120 may be accommodated in the pharmaceutical composition container 10 shown in FIG.
  • the shape of the inclusion is not limited to that shown in FIGS.
  • the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing moisture.
  • the surface of the capsule melt
  • the capsule dissolves in the digestive juice inside the stomach and intestines.
  • FIG. 4 is a partially cutaway view of the pharmaceutical composition container 14 according to the second modification.
  • a swallowing auxiliary substance storage chamber 102, a first storage container storage chamber 112, a second storage container storage chamber 114, and an outlet chamber 150 are formed in the pharmaceutical composition container 14.
  • the swallowing auxiliary substance storage chamber 102, the first storage container storage chamber 112, the second storage container storage chamber 114, and the outlet chamber 150 are arranged in a line. Note that the end of the first storage container chamber 112 on the second storage container chamber 114 side becomes narrower as it approaches the second storage container chamber 114 and is stored in the first storage container chamber 112.
  • the object 42 Since the object 42 is accommodated, when the inclusion 42 is pushed out by the swallowing auxiliary substance 40, it can be smoothly performed. Since the end of the second storage chamber 114 on the outlet chamber 150 side becomes narrower as it approaches the outlet chamber 150, and the storage 42 is stored in the second storage chamber 114, this end The inclusion 42 is also pushed out with the same smoothness.
  • a bag-shaped storage 120 instead of storing the storage 42 in the first storage chamber 112 and the second storage chamber 114, a bag-shaped storage 120 as shown in FIG. 3 may be stored.
  • FIG. 5 is a partially cutaway view of a pharmaceutical composition container 15 according to a third modification.
  • a vacant chamber 116 is provided instead of the first storage container chamber 112 shown in FIG. If the vacant chamber 116 is provided, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be reduced to some extent even if the sealing performance between the spaces is impaired due to an accident. If the pharmaceutical composition container 15 can be bent at the portion of the empty space 116, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be further reduced by bending that portion.
  • the pharmaceutical composition container is not limited to a laminate of two sheets.
  • FIG. 6 is a partially cutaway view of the pharmaceutical composition container 16 according to the fourth modification.
  • FIG. 7 is a partially cutaway view of a pharmaceutical composition container 18 according to a fifth modification. These are formed by folding one sheet in half.
  • the pharmaceutical composition containers 16 and 18 are formed by folding one sheet in half, the swallowing assistance substance containing chamber 104, compared to the pharmaceutical composition container formed by bonding two sheets with the same outer diameter.
  • the volume of 106 can be increased.
  • the pharmaceutical composition container may be obtained by pasting together portions of one tube.
  • the cut portion 50 is configured with a V-shaped cut, but the cut portion of the present invention may have a shape other than the V shape.
  • the pharmaceutical composition is a powder or a granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto.
  • the pharmaceutical composition may be a tablet, a capsule or a simple lump in addition to a powder or a granule.
  • the swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to the aqueous solution.
  • molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical.
  • the product molded as a pharmaceutical composition may be a food that has been recognized to improve health.
  • materials for the inclusions various materials conventionally used as materials for edible films can be used in addition to the above-mentioned 10 ⁇ m thick starch oblate. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.
  • polysaccharides eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.
  • peptide substances eg, gelatin, silk protein degradation products, casein
  • the outlet chambers 34 and 150 are described. However, the outlet chamber 34 is not provided, and the notch 50 is provided in the storage chamber 32 or the like. An opening may be provided by applying a shearing force to the portion 50, and the opening may be applied to the patient's mouth.
  • the structure of 70, 71, 72 between two adjacent spaces may be different from that described above.
  • a thin film may be formed between two adjacent spaces 70, 71, 72.
  • Such a film can be formed by sandwiching a member to be a film between two sheets 20 and 20 and bonding them together.
  • the structure of 70, 71, 72 between two adjacent spaces must be a structure that is closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10.
  • This “force applied from the outside of the pharmaceutical composition container 10” may be a force directly applied to 70, 71, 72 between two adjacent spaces, or a force indirectly applied to one of them. There may be.
  • FIG. 8 is a partially cutaway view of the pharmaceutical composition container 11 according to the sixth modification.
  • a first bag storage chamber 36, a second bag storage chamber 38, a stored item storage chamber 32, and an outlet chamber 34 are formed. Similar to the container storage chamber 32 and the outlet chamber 34, the first bag storage chamber 36 and the second bag storage chamber 38 are also formed so as to be airtight with respect to the external space.
  • the first bag storage chamber 36 and the second bag storage chamber 38 store the auxiliary substance storage bag 22 and fix it. It is the outer peripheral strong seal portion 74 and the third weak seal portion 76 that directly fix the auxiliary substance containing bag 22.
  • the strength of the third weak seal portion 76 against peeling is substantially the same as that of the outer peripheral strong seal portion 74.
  • the auxiliary substance storage bag 22 stores the swallowing auxiliary substance 40.
  • the strength of one end of the auxiliary substance storage bag 22 facing the first weak seal portion 70 is a strength that is broken by a force applied from the outside of the pharmaceutical composition container 11.
  • the swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 22, and is then sandwiched between the sheets 20 and 20 and adhered thereto. Thereafter, the outer peripheral strong seal portion 74 and the like are formed. Thereby, when force is applied from the outside of the pharmaceutical composition container 11, one end of the auxiliary substance storage bag 22 is peeled off. When it is peeled off, the swallowing auxiliary substance 40 leaks into the first bag storage chamber 36.
  • the first weak seal portion 70 is peeled by the force received from the swallowing auxiliary substance 40.
  • the inclusion 42 is wrapped in the swallowing aid substance 40.
  • the pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine.
  • the container for taking medicine can be suitably used for a medicine filled by the following system.
  • the system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, and connected to a pharmaceutical production line to perform automatic operation for a long time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a pharmaceutical composition container which can be swallowed easily while controlling a pharmaceutical composition from scattering in mouth and can be filled with a pharmaceutical composition easily. A pharmaceutical composition container (10) is equipped with a plurality of spaces (30, 32, 50). The portions (70, 72) between two adjacent spaces are closed. The portions (70, 72) between two adjacent spaces are opened when a force is applied from the outside of the pharmaceutical composition container (10). A deglutition assistance material (40) is contained in a deglutition assistance material containing chamber (30). A concealment material (42) is contained in a concealment material containing chamber (32). The concealment material (42) conceals a pharmaceutical composition (80). A sheet (20) is provided with a portion (60) where an opening is scheduled to be formed. The opening interconnects the outside of the pharmaceutical composition container (10) and the spaces (30, 32, 50).

Description

医薬組成物容器Pharmaceutical composition container
　本発明は、医薬組成物容器に関し、さらに詳しくは、医薬組成物の残留量を低下させることができるようにした、医薬組成物容器に関する。 The present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container capable of reducing the residual amount of the pharmaceutical composition.
　散剤や顆粒剤のような医薬組成物を服用する場合、一般に水を利用して嚥下される。しかしこの医薬組成物は、一旦舌上に受けたのち水を飲み込むことで嚥下されることから、一部がいつまでも口内などに残留したり、薬効成分による刺激を受けたりする問題があるうえ、流動性の高い水で服用するため、横臥した状態で服用することができないなどの問題がある。 When taking a pharmaceutical composition such as powder or granule, it is generally swallowed using water. However, since this pharmaceutical composition is swallowed by swallowing water once it is received on the tongue, there is a problem that a part of the composition remains in the mouth forever or is stimulated by medicinal ingredients, Because it is taken with high-quality water, there are problems such as being unable to take it lying down.
　特許文献１は、複室型容器を開示する。この複室型容器は、複数の空間を互いに連通可能に区画したものである。これらの空間は、外部から加えられる力によって連通可能な状態で閉塞されている。これらの空間のいずれかに、粉粒状剤が密封状態で収容されている。他の空間には濃厚流動物質が密封状態で収容されている。各空間を互いに連通させて、粉粒状剤と濃厚流動物質とを集合させ混合したのち、いずれかの空間に設けた取出し口より混合物を取出し可能である。 Patent Document 1 discloses a multi-chamber container. This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state. The other space contains a dense fluid substance in a sealed state. Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.
　特許文献１に開示された容器によれば、極めて簡単な操作で粉粒状剤を服用することができる。しかも、特許文献１に開示された複室型容器によれば、服用に対する患者の抵抗感を大幅に減じることができる。
特開平１０－２３４８２０号公報 According to the container disclosed in Patent Document 1, it is possible to take the granular agent by an extremely simple operation. In addition, according to the multi-chamber container disclosed in Patent Document 1, the patient's resistance to taking can be greatly reduced.
Japanese Patent Laid-Open No. 10-234820
　しかしながら、特許文献１に開始された発明では、医薬組成物が粉末や散剤や顆粒剤である場合、それらが複室型容器内に残留する可能性が高いという問題点がある。 However, in the invention started in Patent Document 1, when the pharmaceutical composition is a powder, powder or granule, there is a problem that there is a high possibility that they remain in the multi-chamber container.
　本発明の技術的課題は上記の問題点を解消するためになされたものであって、その目的は、医薬組成物の残留量を低下させることができる、医薬組成物容器を提供することにある。 The technical problem of the present invention was made to solve the above problems, and an object of the present invention is to provide a pharmaceutical composition container that can reduce the residual amount of the pharmaceutical composition. .
　図面を参照して本発明の医薬組成物容器を説明する。なお、この欄で図中の符号を使用したのは、発明の内容の理解を助けるためであって、内容を図示した範囲に限定する意図ではない。 The pharmaceutical composition container of the present invention will be described with reference to the drawings. Note that the use of the reference numerals in the figure in this column is intended to assist understanding of the contents of the invention, and is not intended to limit the contents to the illustrated range.
　上記目的を達成するために、本発明のある局面に従うと、医薬組成物容器１０，１１，１２，１４，１５，１６，１８は、複数の空間３０，３２，３４，３６，３８，１００，１０２，１１０，１１２，１１４，１１６，１５０を備えるものである。隣り合う２つの空間の間７０，７１，７２，７６は閉塞されている。隣り合う２つの空間の間７０，７１，７２，７６は、医薬組成物容器１０，１１，１２，１４，１５，１６，１８の外部から力が加えられると開く。空間のうち少なくとも１つである嚥下補助物質収容室３０，１００，１０２，１０４，１０６に嚥下補助物質４０が収容されている。空間のうち少なくとも１つである包蔵物収容室３２，１１０に包蔵物４２，１２０が収容されている。包蔵物４２，１２０には医薬組成物８０が入っている。医薬組成物容器１０，１１，１２，１４，１５，１６，１８には、開口形成予定部６０が設けられている。開口形成予定部６０は、開口の形成が予定される部分である。開口は、医薬組成物容器１０，１１，１２，１４，１５，１６，１８の外部と空間３０，３２，３４，３６，３８，１００，１０２，１１０，１１２，１１４，１１６，１５０とを連通させる。 In order to achieve the above object, according to one aspect of the present invention, the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 has a plurality of spaces 30, 32, 34, 36, 38, 100, 102,110,112,114,116,150. Between two adjacent spaces 70, 71, 72, 76 are closed. The space 70, 71, 72, 76 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18. The swallowing assisting substance 40 is accommodated in the swallowing assisting substance accommodating chambers 30, 100, 102, 104, 106 which are at least one of the spaces. The storages 42 and 120 are stored in the storage chambers 32 and 110, which are at least one of the spaces. The inclusions 42 and 120 contain a pharmaceutical composition 80. The pharmaceutical composition containers 10, 11, 12, 14, 15, 16, 18 are provided with an opening formation scheduled portion 60. The opening formation scheduled portion 60 is a portion where the opening is scheduled to be formed. The opening communicates the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 with the spaces 30, 32, 34, 36, 38, 100, 102, 110, 112, 114, 116, 150. Let
　隣り合う２つの空間の間７０，７１，７２，７６は閉塞されている。隣り合う２つの空間の間７０，７１，７２，７６は、医薬組成物容器１０，１１，１２，１４，１５，１６，１８の外部から加えられる力が加えられると開く。隣り合う２つの空間の間７０，７１，７２，７６が開くことで、嚥下補助物質４０を嚥下補助物質収容室３０，１００，１０２，１０４，１０６から包蔵物収容室３２，１１０，１１２，１１４へ誘導することが可能になる。これにより、開口形成予定部６０に開口が設けられた後にその開口を嚥下が困難な者の口にあて、嚥下補助物質４０と包蔵物４２とをその開口から押し出すと、嚥下補助物質４０に包まれた状態で嚥下が困難な者の口の中に包蔵物４２が入る。包蔵物４２は嚥下される。医薬組成物８０は包蔵物４２の中に入っているので、包蔵物４２が押し出された際、包蔵物４２の中の医薬組成物８０も同時に押し出される。その結果、医薬組成物８０が包蔵物４２の中に入っていない場合に比べ、包蔵物収容室３２内における医薬組成物８０の残留量は低下する。 Between the two adjacent spaces, 70, 71, 72, 76 are closed. The space 70, 71, 72, 76 between two adjacent spaces opens when a force applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 is applied. By opening 70, 71, 72, 76 between two adjacent spaces, the swallowing auxiliary substance 40 is moved from the swallowing auxiliary substance containing chambers 30, 100, 102, 104, 106 to the inclusion holding chambers 32, 110, 112, 114. It becomes possible to guide to. Thus, after the opening is formed in the opening formation scheduled portion 60, the opening is applied to the mouth of a person who has difficulty in swallowing, and when the swallowing auxiliary substance 40 and the inclusion 42 are pushed out of the opening, the swallowing auxiliary substance 40 is wrapped. The inclusion 42 enters the mouth of a person who is difficult to swallow in a rare state. The inclusion 42 is swallowed. Since the pharmaceutical composition 80 is contained in the storage 42, when the storage 42 is pushed out, the pharmaceutical composition 80 in the storage 42 is also pushed out at the same time. As a result, the residual amount of the pharmaceutical composition 80 in the storage container 32 is lower than when the pharmaceutical composition 80 is not contained in the storage 42.
　また、上述した嚥下補助物質４０が水分を含有していることが望ましい。この場合、包蔵物４２の材質は水溶性物質である。これにより、包蔵物４２の表面が十分溶けないため嚥下が困難になる可能性は低くなる。 In addition, it is desirable that the above-described swallowing auxiliary substance 40 contains water. In this case, the material of the inclusion 42 is a water-soluble substance. Thereby, since the surface of the inclusion 42 does not melt | dissolve enough, possibility that it will become difficult to swallow becomes low.
　もしくは、上述した嚥下補助物質４０が水分を含むゼリーであることが望ましい。この場合、水溶性物質がデンプンであることが望ましい。 Alternatively, it is desirable that the above-described swallowing aid substance 40 is a jelly containing moisture. In this case, it is desirable that the water-soluble substance is starch.
　また、上述した空間のうち少なくとも１つである空室１１６が、嚥下補助物質収容室１０２と包蔵物収容室３２，１１４との間に配置されていることが望ましい。空室１１６が設けられていると、医薬組成物容器１５の使用者や取扱者の意図に反して隣り合う２つの空間１０２，１１４の間が連通したときに、嚥下補助物質４０が包蔵物４２に接触する可能性が低くなる。その可能性が低くなると、医薬組成物８０の服用前に包蔵物４２が溶解してしまう可能性も低くなる。その結果、医薬組成物容器１５が保存しやすくなり、かつ、取扱が容易になるためである。 In addition, it is desirable that an empty room 116, which is at least one of the above-described spaces, be disposed between the swallowing auxiliary substance storage chamber 102 and the stored material storage chambers 32 and 114. When the vacant space 116 is provided, the swallowing aid substance 40 is contained in the inclusion 42 when the two adjacent spaces 102 and 114 communicate with each other against the intention of the user or the handler of the pharmaceutical composition container 15. The possibility of touching is reduced. If the possibility becomes low, the possibility that the encapsulated material 42 will dissolve before taking the pharmaceutical composition 80 also becomes low. As a result, the pharmaceutical composition container 15 is easy to store and easy to handle.
　また、上述した包蔵物４２のうち少なくとも表面が嚥下補助物質４０の成分に対して溶解することが望ましい。包蔵物４２のうち少なくとも表面が嚥下補助物質４０の成分に対して溶解すると、嚥下補助物質４０が包蔵物収容室３２に誘導された後、包蔵物４２の表面が溶けることとなる。嚥下補助物質４０に包まれた上、表面が溶けているので、嚥下が困難な者であってもその包蔵物４２を容易に嚥下することができる。包蔵物４２を嚥下することで医薬組成物８０も嚥下されることとなる。 In addition, it is desirable that at least the surface of the inclusion 42 described above dissolves in the components of the swallowing auxiliary substance 40. When at least the surface of the inclusion 42 is dissolved with respect to the component of the swallowing auxiliary substance 40, after the swallowing auxiliary substance 40 is guided to the inclusion containing chamber 32, the surface of the inclusion 42 is dissolved. Since the surface is melted while being wrapped in the swallowing auxiliary substance 40, even if it is difficult for the person to swallow, the stored item 42 can be swallowed easily. By swallowing the inclusion 42, the pharmaceutical composition 80 is also swallowed.
　また、上述した包蔵物４２が密封されていることが望ましい。なお、本明細書における「密封」とは、隙間のないように塞がれていることを意味する。 In addition, it is desirable that the above-mentioned inclusion 42 is sealed. In addition, “sealing” in the present specification means being closed so that there is no gap.
　本発明によれば、医薬組成物の残留量を低下させることができる。 According to the present invention, the residual amount of the pharmaceutical composition can be reduced.
本発明の実施形態にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning embodiment of this invention. 本発明の実施形態にかかる医薬組成物容器の使用状況を示す図である。It is a figure which shows the use condition of the pharmaceutical composition container concerning embodiment of this invention. 本発明の第１変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 1st modification of this invention. 本発明の第２変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 2nd modification of this invention. 本発明の第３変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 3rd modification of this invention. 本発明の第４変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 4th modification of the present invention. 本発明の第５変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 5th modification of this invention. 本発明の第６変形例にかかる医薬組成物容器の一部破断図である。It is a partially broken figure of the pharmaceutical composition container concerning the 6th modification of this invention.
符号の説明Explanation of symbols
１０，１１，１２，１４，１５，１６，１８　　医薬組成物容器
２０　シート
２２　補助物質収容袋
３０，１００，１０２，１０４，１０６　嚥下補助物質収容室
３２，１１０　　　 包蔵物収容室
３４，１５０　　　 出口室
３６　第１袋収容室
３８　第２袋収容室
４０　嚥下補助物質
４２，１２０　　　 包蔵物
５０　切込部
６０　開口形成予定部
７０　第１弱シール部分
７２　第２弱シール部分
７４　外周強シール部分
７６　第３弱シール部分
８０　医薬組成物
１１２　　　第１包蔵物収容室
１１４　　　第２包蔵物収容室
１１６　　　空室
１３０　　　第１テーパ部分
１４０　　　第２テーパ部分 10, 11, 12, 14, 15, 16, 18 Pharmaceutical composition container 20 Sheet 22 Auxiliary substance storage bag 30, 100, 102, 104, 106 Swallowing auxiliary substance storage chamber 32, 110 Receptacle storage chamber 34, 150 Exit chamber 36 1st bag storage chamber 38 2nd bag storage chamber 40 Swallowing assisting substances 42 and 120 The inclusion 50 The cut part 60 The opening formation scheduled part 70 The 1st weak seal part 72 The 2nd weak seal part 74 The outer periphery strong seal part 76 3rd Weak seal portion 80 Pharmaceutical composition 112 First storage chamber 114 Second storage chamber 116 Empty space 130 First taper portion 140 Second taper portion
　以下、本発明の実施形態を図面に基づき説明する。以下の説明では、同一の部品には同一の符号を付してある。それらの名称および機能も同一である。したがって、それらについての詳細な説明は繰返さない。 Hereinafter, embodiments of the present invention will be described with reference to the drawings. In the following description, the same parts are denoted by the same reference numerals. Their names and functions are also the same. Therefore, detailed description thereof will not be repeated.
　図１は本実施形態にかかる医薬組成物容器１０の一部破断図である。図２は、本実施形態に係る医薬組成物容器１０の使用状況を示す図である。 FIG. 1 is a partially cutaway view of a pharmaceutical composition container 10 according to the present embodiment. FIG. 2 is a diagram illustrating a usage state of the pharmaceutical composition container 10 according to the present embodiment.
　本実施形態にかかる医薬組成物容器１０は、互いに重ね合わせた２枚の合成樹脂（低密度ポリエチレンなどのように、折畳みが可能な柔らかいものが好ましい。）製のシート２０，２０の周囲を貼り合わせることで形成されている。医薬組成物容器１０には、嚥下補助物質収容室３０と包蔵物収容室３２と出口室３４とが形成されている。嚥下補助物質収容室３０と包蔵物収容室３２と出口室３４とは、外部空間に対して気密性を保つように形成されている。嚥下補助物質収容室３０と包蔵物収容室３２と出口室３４とは、一列に並んでいる。 The pharmaceutical composition container 10 according to the present embodiment is affixed around the sheets 20 and 20 made of two synthetic resins that are superposed on each other (preferably a soft material that can be folded, such as low-density polyethylene). It is formed by combining. In the pharmaceutical composition container 10, a swallowing auxiliary substance storage chamber 30, a stored material storage chamber 32, and an outlet chamber 34 are formed. The swallowing auxiliary substance storage chamber 30, the inclusion storage chamber 32, and the outlet chamber 34 are formed so as to maintain airtightness with respect to the external space. The swallowing auxiliary substance storage chamber 30, the stored item storage chamber 32, and the outlet chamber 34 are arranged in a line.
　嚥下補助物質収容室３０内には、嚥下補助物質４０が収容されている。本実施形態における嚥下補助物質４０は、水分を含有する、滅菌されたゼリーである。本実施形態において、ゼリーの含水率は、嚥下補助物質４０が後述する包蔵物４２の表面を覆った時から包蔵物４２が完全に溶けるまでの時間を少なくとも２分確保できるように設定される。後述する第２弱シール部分７２が剥離するまで、本実施形態における出口室３４は空室である。 A swallowing assistance substance 40 is housed in the swallowing assistance substance accommodation chamber 30. The swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water. In the present embodiment, the moisture content of the jelly is set so as to ensure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the inclusion 42 described later until the inclusion 42 is completely dissolved. Until the 2nd weak seal part 72 mentioned later peels, the exit chamber 34 in this embodiment is an empty room.
　包蔵物収容室３２内には、オブラートで作られた包蔵物４２が収容されている。包蔵物４２内には、顆粒状の薬剤その他の医薬組成物８０が収容されている。本実施形態に係る包蔵物４２は、市販のオブラートに医薬組成物８０を入れ、医薬組成物８０の入口にあたる部分を捻ったものである。これにより、包蔵物４２が密封されていることになる。ただし、本実施形態においては、厚さ１０μｍのデンプン製のオブラートを用いている。これが用いられるのは、嚥下補助物質４０が包蔵物４２の表面を覆った時から包蔵物４２が完全に溶けるまでの時間を少なくとも２分確保するためである。もちろん、オブラートの厚さはその材質に応じて適宜選択されるべきものである。 In the storage room 32, a storage 42 made of oblate is stored. A granulated drug or other pharmaceutical composition 80 is accommodated in the inclusion 42. The inclusion 42 according to the present embodiment is obtained by putting the pharmaceutical composition 80 in a commercially available wafer and twisting a portion corresponding to the entrance of the pharmaceutical composition 80. Thereby, the stored item 42 is sealed. However, in this embodiment, a starch wafer having a thickness of 10 μm is used. This is used in order to secure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the storage 42 until the storage 42 is completely dissolved. Of course, the thickness of the wafer should be appropriately selected according to the material.
　なお、包蔵物収容室３２と嚥下補助物質収容室３０とには、医薬組成物８０や嚥下補助物質４０に影響を与えない気体（例えば窒素ガス）が、必要に応じて封入してある。 It should be noted that a gas (for example, nitrogen gas) that does not affect the pharmaceutical composition 80 and the swallowing auxiliary substance 40 is sealed in the storage container 32 and the swallowing auxiliary substance holding room 30 as necessary.
　嚥下補助物質収容室３０と包蔵物収容室３２との間は、第１弱シール部分７０によって仕切られている。包蔵物収容室３２と出口室３４との間は、第２弱シール部分７２によって仕切られている。第１弱シール部分７０と第２弱シール部分７２とは、２枚のシート２０，２０の貼り合せ部分のうち、隣り合う２つの空間の間にあたる部分である。第１弱シール部分７０と第２弱シール部分７２との強度は、外周強シール部分７４（２枚のシート２０，２０が貼り合された部分のうち、第１弱シール部分７０および第２弱シール部分７２以外の部分のこと）の強度よりも低くなっている。これは、２枚のシート２０，２０を貼り合せる際、接着剤として用いる素材を別のものとすることで可能になる。その結果、第１弱シール部分７０と第２弱シール部分７２とは、嚥下補助物質収容室３０あるいは包蔵物収容室３２を医薬組成物容器１０の外から押したとき、嚥下補助物質収容室３０あるいは包蔵物収容室３２に嚥下補助物質４０が与える力によって容易に剥離する。すなわち、嚥下補助物質収容室３０と包蔵物収容室３２との間は、医薬組成物容器１０の外部から加えられる力によって連通可能な状態で閉塞されている。 The swallowing auxiliary substance storage chamber 30 and the stored material storage chamber 32 are partitioned by a first weak seal portion 70. The inclusion storage chamber 32 and the outlet chamber 34 are partitioned by a second weak seal portion 72. The first weak seal portion 70 and the second weak seal portion 72 are portions between two adjacent spaces among the bonded portions of the two sheets 20 and 20. The strength of the first weak seal portion 70 and the second weak seal portion 72 is such that the outer peripheral strong seal portion 74 (the first weak seal portion 70 and the second weak seal among the portions where the two sheets 20 and 20 are bonded together). It is lower than the strength of the portion other than the seal portion 72). This can be achieved by using different materials for the adhesive when the two sheets 20 and 20 are bonded together. As a result, when the first weak seal portion 70 and the second weak seal portion 72 are pushed from the outside of the pharmaceutical composition container 10 when the swallowing auxiliary substance storage chamber 30 or the inclusion storage chamber 32 is pushed out of the pharmaceutical composition container 10, the swallowing auxiliary substance storage chamber 30. Or it peels easily with the force which the swallowing auxiliary | assistance substance 40 gives to the storage container 32. In other words, the swallowing auxiliary substance storage chamber 30 and the stored material storage chamber 32 are closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10.
　出口室３４の両側方には、Ｖ字形の切り口からなる一対の切込部５０が形成されている。切込部５０で挟まれる開口形成予定部６０は、開口の形成が予定される部分である。この開口は、出口室３４の外部と内部とを連通させる。 A pair of cut portions 50 each having a V-shaped cut are formed on both sides of the exit chamber 34. The opening formation scheduled portion 60 sandwiched between the cut portions 50 is a portion where the opening is scheduled to be formed. This opening allows the outside and the inside of the outlet chamber 34 to communicate with each other.
　図２を参照しつつ、医薬組成物８０を医薬組成物容器１０から取り出して服用するための手順を説明する。 Referring to FIG. 2, a procedure for taking out the pharmaceutical composition 80 from the pharmaceutical composition container 10 and taking it will be described.
　最初に、介護者などが嚥下補助物質収容室３０を医薬組成物容器１０の外から押して、嚥下補助物質収容室３０の内部からの圧力により第１弱シール部分７０を剥離させる。第１弱シール部分７０が剥離されると、嚥下補助物質４０が包蔵物収容室３２に押し出される。押し出された嚥下補助物質４０は、包蔵物収容室３２の中に拡がり、包蔵物４２の周囲に充満する。この時から、包蔵物４２の表面は、嚥下補助物質４０によって溶け始める。 First, a caregiver or the like pushes the swallowing auxiliary substance storage chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal portion 70 by pressure from the inside of the swallowing auxiliary substance storage chamber 30. When the first weak seal portion 70 is peeled off, the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32. The pushed swallowing auxiliary substance 40 spreads in the storage container chamber 32 and fills the periphery of the storage object 42. From this time, the surface of the inclusion 42 starts to melt by the swallowing aid 40.
　嚥下補助物質４０が包蔵物収容室３２に押し出された後、介護者や患者９０などが、嚥下補助物質収容室３０から包蔵物収容室３２へ向かう方向に医薬組成物容器１０をしごく。これにより、嚥下補助物質４０に圧力が加えられた結果、第２弱シール部分７２が剥離される。第２弱シール部分７２が剥離されると、嚥下補助物質４０と包蔵物４２とが出口室３４に押し出される。嚥下補助物質４０と包蔵物４２とが出口室３４に押し出されると、介護者や患者９０などが、切込部５０にせん断力を加え、出口室３４に開口を設ける。開口が設けられると、介護者や患者９０などが、患者の口にその開口をあて、嚥下補助物質収容室３０から包蔵物収容室３２の方向へ医薬組成物容器１０をしごく。これにより、嚥下補助物質４０に覆われた包蔵物４２が患者９０の口の中に入る。図２は、患者９０が医薬組成物容器１０をしごいている状況を示す。このとき、包蔵物４２の表面が嚥下補助物質４０の成分に溶けているため、包蔵物４２の表面はすべりやすくなっている。包蔵物４２の表面がすべりやすくなっているため、包蔵物４２はスムーズに嚥下される。 After the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32, a caregiver, a patient 90, or the like squeezes the pharmaceutical composition container 10 in the direction from the swallowing auxiliary substance storage chamber 30 toward the storage container chamber 32. Thereby, as a result of the pressure being applied to the swallowing auxiliary substance 40, the second weak seal portion 72 is peeled off. When the second weak seal portion 72 is peeled off, the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34. When the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34, a caregiver, a patient 90, or the like applies a shearing force to the incision portion 50 to provide an opening in the outlet chamber 34. When the opening is provided, a caregiver, a patient 90, or the like places the opening on the patient's mouth and squeezes the pharmaceutical composition container 10 from the swallowing auxiliary substance storage chamber 30 toward the storage container 32. As a result, the inclusion 42 covered with the swallowing auxiliary substance 40 enters the mouth of the patient 90. FIG. 2 shows a situation where the patient 90 is squeezing the pharmaceutical composition container 10. At this time, since the surface of the inclusion 42 is dissolved in the component of the swallowing auxiliary substance 40, the surface of the inclusion 42 is easily slipped. Since the surface of the inclusion 42 is easy to slide, the inclusion 42 is swallowed smoothly.
　以上のようにして、本実施形態にかかる医薬組成物容器１０は、次に述べる効果を奏する。第１の効果は、顆粒状の薬剤その他の医薬組成物８０を容易に嚥下することができるという効果である。第２の効果は、薬剤の苦味などの味が抑制されるという効果である。第３の効果は、医薬組成物８０が口内で散乱することを抑制できるという効果である。第４の効果は、薬剤の安定性を懸念する必要がなくなるという効果である。第５の効果は、嚥下が困難な者に対してさまざまな種類の固体を服用させることができるという効果である。第６の効果は、医薬組成物容器１０の内部における医薬組成物８０の残留量を低下させる（本実施形態の場合ならば、残留量をゼロに近い量にする）ことができるという効果である。 As described above, the pharmaceutical composition container 10 according to the present embodiment has the following effects. The first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily. The second effect is that the taste such as the bitterness of the drug is suppressed. The third effect is an effect that the pharmaceutical composition 80 can be prevented from being scattered in the mouth. The fourth effect is that there is no need to worry about the stability of the drug. The fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing. The sixth effect is that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (in the case of the present embodiment, the residual amount can be made an amount close to zero). .
　第１の効果について詳細に説明する。嚥下補助物質４０に包まれた状態で患者９０の口の中に包蔵物４２が入る。このとき、包蔵物４２の表面は溶けている。嚥下補助物質４０に包まれた上、表面が溶けているので、嚥下が困難な患者９０であってもその包蔵物４２を容易に嚥下することができる。包蔵物４２には医薬組成物８０が入っているので、包蔵物４２を嚥下することで医薬組成物８０も嚥下されることとなる。これにより、医薬組成物８０を容易に嚥下することができる。 The first effect will be described in detail. The inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. At this time, the surface of the inclusion 42 is melted. Since the surface is melted while being wrapped in the swallowing assisting material 40, even the patient 90 who is difficult to swallow can easily swallow the stored matter 42. Since the encapsulated product 42 contains the pharmaceutical composition 80, the medicinal composition 80 is also swallowed by swallowing the encapsulated product 42. Thereby, the pharmaceutical composition 80 can be swallowed easily.
　第２の効果について詳細に説明する。上述したように、嚥下補助物質４０に包まれた状態で患者９０の口の中に包蔵物４２が入る。これにより、包蔵物４２の中身である医薬組成物８０は、嚥下補助物質４０と包蔵物４２とにより二重に包まれていることとなる。医薬組成物８０が二重に包まれているため、医薬組成物８０が薬剤であっても、患者９０の舌がその苦味などの味を感じ取る可能性は低くなる。その結果、薬剤の苦味などの味が抑制される。 The second effect will be described in detail. As described above, the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. Thereby, the pharmaceutical composition 80 which is the content of the stored product 42 is double-wrapped by the swallowing auxiliary substance 40 and the stored product 42. Since the pharmaceutical composition 80 is wrapped in a double layer, even if the pharmaceutical composition 80 is a drug, the possibility that the tongue of the patient 90 senses its taste such as bitterness is low. As a result, the taste such as the bitterness of the drug is suppressed.
　第３の効果について詳細に説明する。上述したように、医薬組成物８０は、嚥下補助物質４０と包蔵物４２とにより二重に包まれている。これにより、患者９０の口内で医薬組成物８０が散乱する可能性は低くなる。その結果、医薬組成物８０が口内で散乱することを抑制できる。 The third effect will be described in detail. As described above, the pharmaceutical composition 80 is double-wrapped by the swallowing auxiliary substance 40 and the inclusion 42. Thereby, the possibility that the pharmaceutical composition 80 is scattered in the mouth of the patient 90 is reduced. As a result, scattering of the pharmaceutical composition 80 in the mouth can be suppressed.
　第４の効果について詳細に説明する。薬剤は化学物質である。化学物質同士が接触すると、多くの場合に化学反応が生じる。化学反応が生じることにより、薬剤は薬効を失う。このため、多くの場合、複数の薬剤を混合状態で保存することはできない。混合状態でそれらを保存する場合、それらの薬効が失われないか予め調べる必要がある。本実施形態にかかる医薬組成物容器１０には複数の空間が設けられている。それらの空間に１種類ずつ薬剤を収容することと、複数の薬剤を別々に保存することとは実質上同一である。これが、本実施形態にかかる医薬組成物容器１０を用いれば薬剤の安定性を懸念しなくてよい理由である。薬剤の安定性を懸念しなくて良いので、複数の薬剤の薬効が失われていないか予め調べる必要もなくなる。 The fourth effect will be described in detail. The drug is a chemical substance. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the drug loses its medicinal properties. For this reason, in many cases, a plurality of drugs cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check in advance whether their medicinal properties are lost. The pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. Storing one type of drug in each space and storing a plurality of drugs separately are substantially the same. This is the reason why it is not necessary to worry about the stability of the drug if the pharmaceutical composition container 10 according to this embodiment is used. Since there is no need to worry about the stability of the drugs, there is no need to examine in advance whether the efficacy of a plurality of drugs has been lost.
　第５の効果について説明する。嚥下補助物質４０を包蔵物収容室３２に誘導した後、嚥下補助物質４０と包蔵物４２とを嚥下することで、医薬組成物８０自体の活性は嚥下の難易度に関してあまり大きな影響を持たなくなる。これにより、嚥下が困難な者に対してさまざまな種類の固体を服用させることができる。 The fifth effect will be described. After the swallowing assisting substance 40 is guided to the storage container chamber 32, the swallowing assisting substance 40 and the storing object 42 are swallowed, so that the activity of the pharmaceutical composition 80 itself does not have a great influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.
　第６の効果について説明する。医薬組成物容器１０に形成された開口から嚥下補助物質４０と包蔵物４２とが押し出されると、包蔵物４２の中の医薬組成物８０も同時に押し出されることとなる。これにより、包蔵物収容室３２の中における医薬組成物８０の残留量は、包蔵物４２の中に医薬組成物８０が入っていない場合に比べ、大幅に少なくなる。しかも、本実施形態にかかる包蔵物４２は密封されている。密封されているので、包蔵物４２の中から医薬組成物８０が漏れ出す可能性は極めて低い。その可能性が極めて低いので、医薬組成物容器１０の内部における医薬組成物８０の残留量を低下させる（実際には、残留量をゼロに近い量にする）ことができる。 The sixth effect will be described. When the swallowing auxiliary substance 40 and the stored product 42 are pushed out from the opening formed in the pharmaceutical composition container 10, the pharmaceutical composition 80 in the stored product 42 is also pushed out at the same time. Thereby, the residual amount of the pharmaceutical composition 80 in the stored material storage chamber 32 is significantly reduced as compared with the case where the stored pharmaceutical product 80 is not contained in the stored product 42. In addition, the container 42 according to the present embodiment is sealed. Since it is sealed, the possibility of the pharmaceutical composition 80 leaking out of the inclusion 42 is very low. Since the possibility is extremely low, the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (actually, the residual amount is made close to zero).
　本実施形態で説明した医薬組成物容器１０は、本発明の技術的思想を具体化するために例示したものである。これは、シート２０の材質を上述した実施形態に限定するものではない。これは、シート２０の形状、各空間の形状、開口の形状、それらの寸法、それらの構造、およびそれらの配置などを上述した実施形態に限定するものでもない。本実施形態で説明した医薬組成物容器１０は、本発明の技術的思想の範囲内において種々の変更を加え得るものである。 The pharmaceutical composition container 10 described in the present embodiment is illustrated to embody the technical idea of the present invention. This does not limit the material of the sheet 20 to the above-described embodiment. This does not limit the shape of the sheet 20, the shape of each space, the shape of the opening, their dimensions, their structure, their arrangement, and the like to the above-described embodiment. The pharmaceutical composition container 10 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.
　例えば、図３は、第１の変形例にかかる医薬組成物容器１２の一部破断図である。この医薬組成物容器１２において、嚥下補助物質収容室１００のうち包蔵物収容室１１０に対向する第１テーパ部分１３０は、包蔵物収容室１１０に向かうにつれ次第に窄まっている。包蔵物収容室１１０のうち嚥下補助物質収容室１００に対向する第２テーパ部分１４０は、嚥下補助物質収容室１００に向かうにつれ次第に窄まっている。これにより、第１弱シール部分７０が剥離され、嚥下補助物質４０が包蔵物収容室１１０に押し出されたとき、嚥下補助物質４０の全量が押し出される可能性が高くなる。 For example, FIG. 3 is a partially cutaway view of the pharmaceutical composition container 12 according to the first modification. In the pharmaceutical composition container 12, the first tapered portion 130 of the swallowing auxiliary substance storage chamber 100 that faces the storage container 110 is gradually narrowed toward the storage container 110. The 2nd taper part 140 which opposes the swallowing auxiliary substance storage chamber 100 among the inclusion storage rooms 110 is gradually narrowed toward the swallowing auxiliary substance storage chamber 100. Thereby, when the 1st weak seal | sticker part 70 is peeled and the swallowing assistance substance 40 is pushed out to the storage container chamber 110, possibility that the whole quantity of the swallowing assistance substance 40 will be pushed out becomes high.
　また、図１に示したような包蔵物４２に代え、図３に示すような袋状の包蔵物１２０が収容されていてもよい。もちろん、包蔵物１２０は図１に示す医薬組成物容器１０に収容されていてもよい。さらに、包蔵物の形状は、図１や図３に示すものに限定されない。例えば、包蔵物４２，１２０に代え、公知のカプセルが包蔵物として収容されてもよい。上述したように、本実施形態における嚥下補助物質４０は、水分を含有する、滅菌されたゼリーである。このため、公知のカプセルが包蔵物として収容されている場合、そのカプセルの表面は嚥下補助物質４０の成分である水分に対して溶解する。その後、胃や腸などの内部で消化液に対してカプセルは溶解する。 Further, instead of the inclusion 42 as shown in FIG. 1, a bag-like inclusion 120 as shown in FIG. 3 may be accommodated. Of course, the stored item 120 may be accommodated in the pharmaceutical composition container 10 shown in FIG. Furthermore, the shape of the inclusion is not limited to that shown in FIGS. For example, instead of the inclusions 42 and 120, a known capsule may be accommodated as the inclusion. As described above, the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing moisture. For this reason, when a well-known capsule is accommodated as a storage thing, the surface of the capsule melt | dissolves with respect to the water | moisture content which is a component of the swallowing assistance substance 40. FIG. Thereafter, the capsule dissolves in the digestive juice inside the stomach and intestines.
　また、１つの医薬組成物容器が備える空間は、２つだけであってもよいし、３つ以上あってもよい。図４は、第２の変形例にかかる医薬組成物容器１４の一部破断図である。医薬組成物容器１４には、嚥下補助物質収容室１０２と第１包蔵物収容室１１２と第２包蔵物収容室１１４と出口室１５０とが形成されている。嚥下補助物質収容室１０２と第１包蔵物収容室１１２と第２包蔵物収容室１１４と出口室１５０とは、一列に並んでいる。なお、第２包蔵物収容室１１４側の第１包蔵物収容室１１２の端部が、第２包蔵物収容室１１４に近付くにつれ狭くなっており、かつ、第１包蔵物収容室１１２内に包蔵物４２が収容されているので、嚥下補助物質４０によって包蔵物４２を押し出す際、それがスムーズに実施できる。出口室１５０側の第２包蔵物収容室１１４の端部が、出口室１５０に近付くにつれ狭くなっており、かつ、第２包蔵物収容室１１４内に包蔵物４２が収容されているので、この包蔵物４２も、同様のスムーズさで押し出される。ちなみに、第１包蔵物収容室１１２と第２包蔵物収容室１１４とに包蔵物４２を収容する代わりに、図３に示すような袋状の包蔵物１２０が収容されていてもよい。 Moreover, the space provided in one pharmaceutical composition container may be only two, or may be three or more. FIG. 4 is a partially cutaway view of the pharmaceutical composition container 14 according to the second modification. In the pharmaceutical composition container 14, a swallowing auxiliary substance storage chamber 102, a first storage container storage chamber 112, a second storage container storage chamber 114, and an outlet chamber 150 are formed. The swallowing auxiliary substance storage chamber 102, the first storage container storage chamber 112, the second storage container storage chamber 114, and the outlet chamber 150 are arranged in a line. Note that the end of the first storage container chamber 112 on the second storage container chamber 114 side becomes narrower as it approaches the second storage container chamber 114 and is stored in the first storage container chamber 112. Since the object 42 is accommodated, when the inclusion 42 is pushed out by the swallowing auxiliary substance 40, it can be smoothly performed. Since the end of the second storage chamber 114 on the outlet chamber 150 side becomes narrower as it approaches the outlet chamber 150, and the storage 42 is stored in the second storage chamber 114, this end The inclusion 42 is also pushed out with the same smoothness. Incidentally, instead of storing the storage 42 in the first storage chamber 112 and the second storage chamber 114, a bag-shaped storage 120 as shown in FIG. 3 may be stored.
　また、嚥下補助物質収容室と包蔵物収容室との間に、空室が設けられていてもよい。空室とは、何も収容されていないか、医薬組成物８０や嚥下補助物質４０に影響を与えない気体が収容されている空間のことである。図５は、第３の変形例にかかる医薬組成物容器１５の一部破断図である。図４に示した第１包蔵物収容室１１２に代え、空室１１６が設けられている。空室１１６が設けられていると、偶発的な事故によって空間の間のシール性が損なわれても、ある程度、嚥下補助物質４０と医薬組成物８０とが混合する可能性を低くできる。空室１１６の部分で医薬組成物容器１５が折り曲げ可能であれば、その部分を折り曲げることで、嚥下補助物質４０と医薬組成物８０とが混合する可能性をさらに低くできる。 In addition, an empty room may be provided between the swallowing assistance substance accommodation room and the storage room. The vacant room is a space in which nothing is accommodated or a gas that does not affect the pharmaceutical composition 80 or the swallowing auxiliary substance 40 is accommodated. FIG. 5 is a partially cutaway view of a pharmaceutical composition container 15 according to a third modification. A vacant chamber 116 is provided instead of the first storage container chamber 112 shown in FIG. If the vacant chamber 116 is provided, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be reduced to some extent even if the sealing performance between the spaces is impaired due to an accident. If the pharmaceutical composition container 15 can be bent at the portion of the empty space 116, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be further reduced by bending that portion.
　また、医薬組成物容器は、２枚のシートを貼り合わせたものに限定されない。図６は、第４の変形例にかかる医薬組成物容器１６の一部破断図である。図７は、第５の変形例にかかる医薬組成物容器１８の一部破断図である。これらは、１枚のシートを二つ折りにして形成されたものである。１枚のシートを二つ折りにして医薬組成物容器１６，１８を形成すると、外径寸法が同一で２枚のシートを貼り合わせて形成した医薬組成物容器に比べ、嚥下補助物質収容室１０４，１０６の容積を増やすことができる。嚥下補助物質収容室１０４，１０６の容積が増えると、嚥下補助物質４０の仕込量を増やすことができる。なお、医薬組成物容器は、１本のチューブのところどころを貼り合わせたものであってもよい。 In addition, the pharmaceutical composition container is not limited to a laminate of two sheets. FIG. 6 is a partially cutaway view of the pharmaceutical composition container 16 according to the fourth modification. FIG. 7 is a partially cutaway view of a pharmaceutical composition container 18 according to a fifth modification. These are formed by folding one sheet in half. When the pharmaceutical composition containers 16 and 18 are formed by folding one sheet in half, the swallowing assistance substance containing chamber 104, compared to the pharmaceutical composition container formed by bonding two sheets with the same outer diameter. The volume of 106 can be increased. When the volume of the swallowing auxiliary substance storage chambers 104 and 106 increases, the amount of swallowing auxiliary substance 40 charged can be increased. In addition, the pharmaceutical composition container may be obtained by pasting together portions of one tube.
　また、上述した医薬組成物容器では、切込部５０をＶ字形の切り口で構成したが、本発明の切込部はＶ字以外の形状であってもよい。 In addition, in the pharmaceutical composition container described above, the cut portion 50 is configured with a V-shaped cut, but the cut portion of the present invention may have a shape other than the V shape.
　また上記の実施形態では、医薬組成物が散剤や顆粒剤であり、嚥下補助物質がゼリーである場合について説明したが、本発明に適用される医薬組成物や嚥下補助物質がこれらに限定されないことはいうまでもない。たとえば、医薬組成物は、散剤や顆粒剤のほか、錠剤やカプセルや単なる塊であってもよい。嚥下補助物質は、水溶液の他、ハチミツ、カスタードクリーム、ピーナツ・スプレッド、チーズ・スプレッドなどであってもよい。さらに、医薬組成物として成形される物は、通常において医薬として扱われる物に限定されない。たとえば、医薬組成物として成形される物は、健康状態を改善する作用が認められている食品であってもよい。 In the above embodiment, the case where the pharmaceutical composition is a powder or a granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto. Needless to say. For example, the pharmaceutical composition may be a tablet, a capsule or a simple lump in addition to a powder or a granule. The swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to the aqueous solution. Furthermore, the thing shape | molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical. For example, the product molded as a pharmaceutical composition may be a food that has been recognized to improve health.
　包蔵物の素材としては、上述した厚さ１０μｍのデンプン製のオブラートの他、従来から可食性フィルムの素材とされている様々な素材を用いることができる。それらの素材の種類には、多糖類（たとえば、プルラン、アラビノキシラン、グアーガム分解物、アルギン酸ナトリウム、カラギーナン、寒天、ペクチン、セルロースなど）、および、ペプチド系物質（たとえば、ゼラチン、絹蛋白分解物、カゼイン分解物など）がある。これらの素材は、１種または２種以上を併せて使用することができる。 As materials for the inclusions, various materials conventionally used as materials for edible films can be used in addition to the above-mentioned 10 μm thick starch oblate. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.
　また上記の実施形態では、出口室３４，１５０が設けられているものを説明したが、出口室３４が設けられておらず、包蔵物収容室３２などに切込部５０を設け、その切込部５０にせん断力を加えて開口を設け、患者の口にその開口をあててもよい。 In the above embodiment, the outlet chambers 34 and 150 are described. However, the outlet chamber 34 is not provided, and the notch 50 is provided in the storage chamber 32 or the like. An opening may be provided by applying a shearing force to the portion 50, and the opening may be applied to the patient's mouth.
　また、隣り合う２つの空間の間７０，７１，７２の構造は、上述したものと異なっていてもよい。例えば、隣り合う２つの空間の間７０，７１，７２の間には、薄い膜が形成されていてもよい。このような膜は、２枚のシート２０，２０に膜となる部材を挟み、それらを貼り合わせることで形成できる。ただし、隣り合う２つの空間の間７０，７１，７２の構造は、医薬組成物容器１０の外部から加えられる力によってそれらが連通可能な状態で閉塞される構造でなくてはならない。この「医薬組成物容器１０の外部から加えられる力」は、隣り合う２つの空間の間７０，７１，７２に直接かかる力であってもよいし、それらのいずれかに間接的にかかる力であってもよい。 Moreover, the structure of 70, 71, 72 between two adjacent spaces may be different from that described above. For example, a thin film may be formed between two adjacent spaces 70, 71, 72. Such a film can be formed by sandwiching a member to be a film between two sheets 20 and 20 and bonding them together. However, the structure of 70, 71, 72 between two adjacent spaces must be a structure that is closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10. This “force applied from the outside of the pharmaceutical composition container 10” may be a force directly applied to 70, 71, 72 between two adjacent spaces, or a force indirectly applied to one of them. There may be.
　また、嚥下補助物質４０は、医薬組成物容器が備える空間に直接充填されていなくともよい。図８は、第６の変形例にかかる医薬組成物容器１１の一部破断図である。本実施形態にかかる医薬組成物容器１１には、第１袋収容室３６と第２袋収容室３８と包蔵物収容室３２と出口室３４とが形成されている。包蔵物収容室３２や出口室３４と同様に、第１袋収容室３６および第２袋収容室３８も、外部空間に対して気密性を保つように形成されている。 Further, the swallowing auxiliary substance 40 may not be directly filled in the space provided in the pharmaceutical composition container. FIG. 8 is a partially cutaway view of the pharmaceutical composition container 11 according to the sixth modification. In the pharmaceutical composition container 11 according to the present embodiment, a first bag storage chamber 36, a second bag storage chamber 38, a stored item storage chamber 32, and an outlet chamber 34 are formed. Similar to the container storage chamber 32 and the outlet chamber 34, the first bag storage chamber 36 and the second bag storage chamber 38 are also formed so as to be airtight with respect to the external space.
　第１袋収容室３６と第２袋収容室３８とは、補助物質収容袋２２を収容し、かつ、それを固定している。補助物質収容袋２２を直接固定しているのは、外周強シール部分７４と、第３弱シール部分７６とである。剥離に対する第３弱シール部分７６の強度は、外周強シール部分７４とほぼ同様である。 The first bag storage chamber 36 and the second bag storage chamber 38 store the auxiliary substance storage bag 22 and fix it. It is the outer peripheral strong seal portion 74 and the third weak seal portion 76 that directly fix the auxiliary substance containing bag 22. The strength of the third weak seal portion 76 against peeling is substantially the same as that of the outer peripheral strong seal portion 74.
　補助物質収容袋２２は、嚥下補助物質４０を収容している。補助物質収容袋２２のうち、第１弱シール部分７０に対向する側の一端の強度は、医薬組成物容器１１の外部から加えられる力によって破壊される強度である。嚥下補助物質４０は、補助物質収容袋２２ごと滅菌された後、シート２０，２０の間に挟まれ、それらに接着される。その後、外周強シール部分７４などが形成される。これにより、医薬組成物容器１１の外部から力を加えると、補助物質収容袋２２の一端が剥離する。そこが剥離すると、嚥下補助物質４０が第１袋収容室３６内に漏出する。このとき、医薬組成物容器１１の外部から力をさらに加えると、嚥下補助物質４０から受ける力により、第１弱シール部分７０が剥離する。第１弱シール部分７０が剥離すると、包蔵物４２は嚥下補助物質４０に包まれる。 The auxiliary substance storage bag 22 stores the swallowing auxiliary substance 40. The strength of one end of the auxiliary substance storage bag 22 facing the first weak seal portion 70 is a strength that is broken by a force applied from the outside of the pharmaceutical composition container 11. The swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 22, and is then sandwiched between the sheets 20 and 20 and adhered thereto. Thereafter, the outer peripheral strong seal portion 74 and the like are formed. Thereby, when force is applied from the outside of the pharmaceutical composition container 11, one end of the auxiliary substance storage bag 22 is peeled off. When it is peeled off, the swallowing auxiliary substance 40 leaks into the first bag storage chamber 36. At this time, when a force is further applied from the outside of the pharmaceutical composition container 11, the first weak seal portion 70 is peeled by the force received from the swallowing auxiliary substance 40. When the first weak seal portion 70 is peeled off, the inclusion 42 is wrapped in the swallowing aid substance 40.
　本発明にかかる医薬組成物容器は、医薬を服用するための容器などに好適に用いることができる。特に、医薬を服用するための容器のうち、次に述べるシステムによって医薬が充填されるものに好適に用いることができる。そのシステムは、オーガー充填機を複数設置し、搬送システム、秤量システムを附加し、医薬製造ラインと接続し、長時間自動運転を行うシステムである。 The pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine. In particular, the container for taking medicine can be suitably used for a medicine filled by the following system. The system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, and connected to a pharmaceutical production line to perform automatic operation for a long time.

Claims (6)

  1. 　複数の空間を備える医薬組成物容器であって、
    　隣り合う２つの前記空間の間は閉塞されており、
    　前記隣り合う２つの空間の間は、前記医薬組成物容器の外部から力が加えられると開き、
    　前記空間のうち少なくとも１つである嚥下補助物質収容室に嚥下補助物質が収容されており、
    　前記空間のうち少なくとも１つである包蔵物収容室に包蔵物が収容されており、
    　前記包蔵物には医薬組成物が入っており、
    　前記医薬組成物容器の外部と前記空間とを連通させる開口の形成が予定される開口形成予定部が設けられていることを特徴とする、医薬組成物容器。     A pharmaceutical composition container comprising a plurality of spaces,
    The space between two adjacent spaces is closed,
    The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
    A swallowing aid substance is housed in a swallowing aid substance storage chamber that is at least one of the spaces,
    A stored item is stored in a stored item storage chamber that is at least one of the spaces,
    The encasement contains a pharmaceutical composition,
    A pharmaceutical composition container characterized in that an opening formation scheduled portion for forming an opening for communicating the outside of the pharmaceutical composition container and the space is provided.
  2. 　前記嚥下補助物質が水分を含有しており、
    　前記包蔵物の材質が水溶性物質であることを特徴とする、請求項１に記載の医薬組成物容器。     The swallowing aid contains water,
    The pharmaceutical composition container according to claim 1, wherein the material of the inclusion is a water-soluble substance.
  3. 　前記嚥下補助物質が水分を含むゼリーであり、
    　前記水溶性物質がデンプンであることを特徴とする、請求項２に記載の医薬組成物容器。     The swallowing aid is a jelly containing water;
    The pharmaceutical composition container according to claim 2, wherein the water-soluble substance is starch.
  4. 　前記空間のうち少なくとも１つである空室が、前記嚥下補助物質収容室と前記包蔵物収容室との間に配置されていることを特徴とする、請求項１に記載の医薬組成物容器。 The pharmaceutical composition container according to claim 1, wherein an empty room which is at least one of the spaces is disposed between the swallowing auxiliary substance storage room and the storage container storage room.
  5. 　前記包蔵物のうち少なくとも表面が前記嚥下補助物質の成分に対して溶解することを特徴とする、請求項１に記載の医薬組成物容器。 The pharmaceutical composition container according to claim 1, wherein at least the surface of the inclusion is dissolved in the swallowing aid component.
  6. 　前記包蔵物が密封されていることを特徴とする、請求項１に記載の医薬組成物容器。 2. The pharmaceutical composition container according to claim 1, wherein the inclusion is sealed.
PCT/JP2009/055972 2009-03-25 2009-03-25 Pharmaceutical composition container WO2010109610A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/JP2009/055972 WO2010109610A1 (en) 2009-03-25 2009-03-25 Pharmaceutical composition container
KR1020117024735A KR20110131295A (en) 2009-03-25 2010-03-25 Medicinal composition container
CN2010800119716A CN102438575A (en) 2009-03-25 2010-03-25 Medicinal composition container
US13/257,424 US20120012480A1 (en) 2009-03-25 2010-03-25 Pharmaceutical composition container
EP10756162.3A EP2412357A4 (en) 2009-03-25 2010-03-25 Medicinal composition container
JP2011506110A JPWO2010110366A1 (en) 2009-03-25 2010-03-25 Pharmaceutical composition container
PCT/JP2010/055212 WO2010110366A1 (en) 2009-03-25 2010-03-25 Medicinal composition container

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/055972 WO2010109610A1 (en) 2009-03-25 2009-03-25 Pharmaceutical composition container

Publications (1)

Publication Number Publication Date
WO2010109610A1 true WO2010109610A1 (en) 2010-09-30

Family

ID=42780319

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2009/055972 WO2010109610A1 (en) 2009-03-25 2009-03-25 Pharmaceutical composition container
PCT/JP2010/055212 WO2010110366A1 (en) 2009-03-25 2010-03-25 Medicinal composition container

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/055212 WO2010110366A1 (en) 2009-03-25 2010-03-25 Medicinal composition container

Country Status (6)

Country Link
US (1) US20120012480A1 (en)
EP (1) EP2412357A4 (en)
JP (1) JPWO2010110366A1 (en)
KR (1) KR20110131295A (en)
CN (1) CN102438575A (en)
WO (2) WO2010109610A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996841B1 (en) * 2013-10-29 2019-07-05 가부시키가이샤 모리모토이야쿠 Divided packet, method of manufacturing divided packet, and device for manufacturing divided packet
WO2015114749A1 (en) * 2014-01-29 2015-08-06 株式会社モリモト医薬 Oral medication-holding cell, strip packaging, and method for manufacturing oral medication-holding cells
JP6514547B2 (en) * 2015-03-31 2019-05-15 株式会社Uacj Double package
GB2542630A (en) * 2015-09-28 2017-03-29 Medimauve Ltd Sachet system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10234820A (en) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd Granular agent jointly using dense fluid substance and double chamber type container therefor
JPH10291538A (en) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc Drug container
JP2000262589A (en) * 1999-03-16 2000-09-26 Jms Co Ltd Double chamber container
JP2007289402A (en) * 2006-04-25 2007-11-08 Takamichi Mukoda Powder medicine and mixing bag for internal liquid medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3070094A (en) * 1959-02-25 1962-12-25 Stanley J Sarnoff Medicament and diluent storing, mixing, and dispensing device
US3478871A (en) * 1968-04-29 1969-11-18 Kleer Vu Ind Inc Burst package with fold seal
US3749620A (en) * 1969-11-20 1973-07-31 American Cyanamid Co Package for plural reactable components with rupturable ultrasonic seal
US4402402A (en) * 1981-10-14 1983-09-06 Pike Brian R Barrier seal multiple-compartment package
US4534509A (en) * 1982-09-28 1985-08-13 Firmenich Sa Multiple compartment plastic packing
GB8911878D0 (en) * 1989-05-24 1989-07-12 Allen Nicholas J Mixing device
US5616337A (en) * 1995-01-30 1997-04-01 Genta Incorporated Unit dose skin care package
US5944709A (en) * 1996-05-13 1999-08-31 B. Braun Medical, Inc. Flexible, multiple-compartment drug container and method of making and using same
JPH11313871A (en) * 1998-05-01 1999-11-16 Hoechst Marion Roussel Kk Infusion vessel
DE10056212B4 (en) * 2000-11-13 2005-08-18 3M Espe Ag Apparatus for storing and dispensing flowable compositions, process for making and using the apparatus
JP2002262589A (en) * 2001-03-01 2002-09-13 Toto Ltd Motor control device
JP4312423B2 (en) * 2002-06-14 2009-08-12 ピジョン株式会社 Enteric capsule
DE10243401B4 (en) * 2002-09-18 2004-07-29 Voco Gmbh Packaging for storing substances and method for producing a directly applicable mixture of two substances from this packaging
WO2004041107A2 (en) * 2002-11-02 2004-05-21 Kettenbach Gmbh & Co. Kg Device for storing and dispensing viscous substances
JP4679838B2 (en) * 2004-06-02 2011-05-11 株式会社細川洋行 Medical chemical container
US7357248B2 (en) * 2004-12-14 2008-04-15 Illinois Tool Works Inc. Point of use cleaning solution
JP4656302B2 (en) * 2005-03-25 2011-03-23 藤森工業株式会社 Multi-chamber container
EP1905455B1 (en) * 2005-06-06 2013-07-24 Ajinomoto Co., Inc. Capsule coating composition
US20070119862A1 (en) * 2005-11-29 2007-05-31 Backes Larry P Unit dose flexible container

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10234820A (en) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd Granular agent jointly using dense fluid substance and double chamber type container therefor
JPH10291538A (en) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc Drug container
JP2000262589A (en) * 1999-03-16 2000-09-26 Jms Co Ltd Double chamber container
JP2007289402A (en) * 2006-04-25 2007-11-08 Takamichi Mukoda Powder medicine and mixing bag for internal liquid medicine

Also Published As

Publication number Publication date
JPWO2010110366A1 (en) 2012-10-04
KR20110131295A (en) 2011-12-06
CN102438575A (en) 2012-05-02
EP2412357A1 (en) 2012-02-01
WO2010110366A1 (en) 2010-09-30
US20120012480A1 (en) 2012-01-19
EP2412357A4 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
JPH05509025A (en) Flexible container and method for forming the same
JP2005523772A (en) Medical multi-chamber container and storage bag for storing the same
TW200911643A (en) Multi-compartment package
WO2010109610A1 (en) Pharmaceutical composition container
EP2702976B1 (en) Container for administering medication
KR101360596B1 (en) Multicompartment container containing a medical solution
WO2010010866A1 (en) Medicine container
JPH10234820A (en) Granular agent jointly using dense fluid substance and double chamber type container therefor
JP2003062038A (en) Chemical container with inner small bag for chemical solution
JP2994417B2 (en) Medicine container
WO2010109612A1 (en) Medical composition container
JP4822860B2 (en) Medical multi-chamber container
JP5781439B2 (en) Formulation for oral administration
JP5792939B2 (en) Pharmaceutical composition container
JP5588967B2 (en) Pharmaceutical composition container
WO2010109611A1 (en) Pharmaceutical composition container
JP5473629B2 (en) Container for swallowing
JP5873483B2 (en) Medication container
WO2014064840A1 (en) Device for oral drug administration
JP2003292055A (en) Container
JP2007105181A (en) Medical dual chamber container

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842224

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842224

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP